CatSci Ltd is excited to participate in the RNA Therapeutics Conference on 10th – 11th February 2025 at Hilton London, Kensington. This event will bring together leading stakeholders to explore the current landscape and future opportunities in oligonucleotides. Over two days of insightful discussions and networking, the conference aims to foster collaborations that accelerate ground-breaking discoveries to market that will advance the next generation of genetic medicine through RNA therapeutics.
Our Business Development Manager, Ali Albeckai, will be attending and looks forward to connecting with peers and industry leaders. Ali will showcase how CatSci’s extensive expertise supports the synthesis of various therapeutic oligonucleotides, including siRNA, ASO, Gapmers, sgRNA, GalNAc ligands, and other conjugates, at scales of up to 30 grams.
CatSci’s cutting-edge capabilities in oligonucleotide R&D and manufacturing are complemented by our GMP-analytical services, method development, and CMC expertise. Our comprehensive approach includes process optimisation for every unit operation in oligonucleotide manufacturing, along with DoE optimisation and Quality by Design (QbD) principles.
If you’re attending RNA Leaders and would like to arrange a meeting with Ali, please get in touch here.
Discover more about our Oligonucleotides capabilities here.
Watch our Director of New Modalities, Dr Nigel Richardson, discuss what oligonucleotides are and how CatSci are advancing the development of these life-changing medicines: